Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting.

First-line CDK4/6 inhibitor ribociclib plus letrozole improves survival in the metastatic setting, but lack of accrual of African American women is a shortcoming. Predicting benefit in the early-stage setting and diverse enrollment in trials need to be priorities. ¹ .
Competing Interests: Declaration of interests The authors declare no competing interests. I-SPY2 Trial and EOP is sponsored by the not for profit Quantum Leap Healthcare Collaborative (QLHC). Dr. Esserman is an unpaid board member of QLHC.
(Copyright © 2022. Published by Elsevier Inc.)